Ahmedabad-based Concord Biotech Limited has announced the successful completion of a National Agency for Food and Drug Administration (NAFDAC) inspection at its Oral Solid Dosage (OSD) Unit-2 facility located in Valthera, Gujarat.
The inspection was conducted between October 6 and October 7, 2025, the company said in a regulatory filing to the BSE and NSE.
Concord Biotech stated that the achievement reflects its commitment to global quality standards, safety, and regulatory compliance, adding that the facility met all inspection parameters without any major observations.
The company emphasized that the successful completion of the NAFDAC inspection reinforces its focus on maintaining excellence in pharmaceutical manufacturing and aligns with its efforts to expand presence in regulated international markets.
Disclaimer: The above information is based on the company’s filing with the exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
